article · Life Cycle
Thromboembolism remains an extremely rare side effect of COVID-19 vaccination, and the benefits of vaccination against COVID-19 continue to outweigh the risks of side effects. The scientific community should have confidence in the safety of the SARS-CoV-2 vaccines when considering solutions to unwanted side effects. This study explores the intricate immunological pathways associated with vaccine-induced immune thrombotic thrombocytopenia (VITT), focusing on the COVID-19 vaccine. The development of VITT is linked to thrombosis, where viral proteins and free DNA in the vaccine bind to platelet factor 4, generating a neo-antigen that induces the production of antibodies promoting platelet activation and clotting. The study sheds light on the complex immunological responses contributing to VITT and its distinction from related syndromes.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.54724/lc.2023.e17
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
